These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9607593)

  • 1. Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro.
    Aschele C; Baldo C; Sobrero AF; Debernardis D; Bornmann WG; Bertino JR
    Clin Cancer Res; 1998 May; 4(5):1323-30. PubMed ID: 9607593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schedule-dependent synergism and antagonism between raltitrexed ("Tomudex") and methotrexate in human colon cancer cell lines in vitro.
    Kano Y; Akutsu M; Tsunoda S; Suzuki K; Yazawa Y; Furukawa Y
    Jpn J Cancer Res; 2001 Jan; 92(1):74-82. PubMed ID: 11173547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schedule-dependent interaction between raltitrexed and 5-fluorouracil in human colon cancer cell lines in vitro.
    Kano Y; Akutsu M; Suzuki K; Yazawa Y; Tsunoda S; Furukawa Y
    Oncol Res; 2000; 12(3):137-48. PubMed ID: 11216672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines.
    Fischel JL; Rostagno P; Formento P; Dubreuil A; Etienne MC; Milano G
    Br J Cancer; 2001 Feb; 84(4):579-85. PubMed ID: 11207057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro.
    Tanaka R; Ariyama H; Qin B; Shibata Y; Takii Y; Kusaba H; Baba E; Mitsugi K; Harada M; Nakano S
    Oncol Rep; 2005 Sep; 14(3):683-8. PubMed ID: 16077975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells.
    Temmink OH; Hoogeland MF; Fukushima M; Peters GJ
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):171-9. PubMed ID: 16010590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).
    Azzariti A; Xu JM; Porcelli L; Paradiso A
    Biochem Pharmacol; 2004 Jul; 68(1):135-44. PubMed ID: 15183125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines.
    Kano Y; Akutsu M; Tsunoda S; Mori K; Suzuki K; Adachi KI
    Cancer Chemother Pharmacol; 1998; 42(2):91-8. PubMed ID: 9654107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic antitumor activity of capecitabine in combination with irinotecan.
    Cao S; Durrani FA; Rustum YM
    Clin Colorectal Cancer; 2005 Jan; 4(5):336-43. PubMed ID: 15663838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations.
    Jackman AL; Kimbell R; Ford HE
    Eur J Cancer; 1999 Mar; 35 Suppl 1():S3-8. PubMed ID: 10645207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity.
    Mullany S; Svingen PA; Kaufmann SH; Erlichman C
    Cancer Chemother Pharmacol; 1998; 42(5):391-9. PubMed ID: 9771954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
    Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
    Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schedule-dependent interactions between raltitrexed and cisplatin in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Suzuki K; Yazawa Y; Tsunoda S
    Jpn J Cancer Res; 2000 Apr; 91(4):424-32. PubMed ID: 10804291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo.
    Anzai H; Frost P; Abbruzzese JL
    Cancer Res; 1992 Apr; 52(8):2180-5. PubMed ID: 1373105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
    Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
    Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Absence of cross resistance between an irinotecan plus cisplatin combination and raltitrexed (ZD1694) in two patients with advanced colorectal cancer].
    Sato A; Kurihara M; Matsukawa M; Yamazaki T; Shimada K; Endo W; Yamazaki T; Nakamachi M
    Gan To Kagaku Ryoho; 2000 Apr; 27(4):617-21. PubMed ID: 10791007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
    Cao S; McGuire JJ; Rustum YM
    Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro sensitivity of human endometrial cancer cell lines to paclitaxel or irinotecan (CPT-11) in combination with other aniticancer drugs.
    Hiramatsu HP; Kikuchi Y; Seto H; Nagata I
    Anticancer Drugs; 2000 Aug; 11(7):573-8. PubMed ID: 11036961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro schedule-dependent interaction between irinotecan and vinorelbine in NCI H460 non-small cell lung cancer cell line.
    Gauvin A; Bressolle F; Martineau P; Astre C; Pinguet F
    Anticancer Res; 2002; 22(2A):905-12. PubMed ID: 12014670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterisation of a synergistic interaction between a thymidylate synthase inhibitor, ZD1694, and a novel lipophilic topoisomerase I inhibitor karenitecin, BNP1100: mechanisms and clinical implications.
    Matsui S; Endo W; Wrzosek C; Haridas K; Seetharamulu P; Hausheer FH; Rustum YM
    Eur J Cancer; 1999 Jun; 35(6):984-93. PubMed ID: 10533483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.